CASI Pharmaceuticals Announces Second Quarter 2021 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/28/2026
- Nasdaq, S&P 500 lifted by Nvidia's forecast; investors eye speech by Fed's Warsh
- Nvidia forecasts 70% sales growth next year, signals AI spending boom has years left to run
- Oil settles up 2% after Trump rejects return to Iran ceasefire deal terms
- Could SpaceX's orbital compute avoid the political headwinds facing data centers?
- Could Meta's teen settlement be less painful than feared? Citi weighs in
- First Financial to acquire Hickory Point Bank in $111.3M deal
- Nasdaq, S&P 500 lifted by Nvidia's forecast; investors eye speech by Fed's Warsh
- Affirm Holdings (AFRM) Tops Q4 EPS by $3.77, Beats on Revenue
- Ovintiv adds 41,000 acres in Permian and Montney deals
- Russia says it could strike UK military targets in response to Kyiv's use of British missiles
CASI Pharmaceuticals (CASI) PT Raised to $6 at Oppenheimer
August 13, 2021 9:21 AM EDTOppenheimer analyst Leland Gershell raised the price target on CASI Pharmaceuticals (NASDAQ: CASI) to $6.00 (from $5.00) while maintaining an Outperform rating.
The analyst commented, "CASI reported another quarter of solid Evomela growth, posting 2Q21 revenue of $7.1M (+25% Q/Q, +173% Y/Y) vs. our $6.2M... More
CASI Pharma (CASI) Tops Q2 EPS by 2c
August 12, 2021 7:18 AM EDTCASI Pharma (NASDAQ: CASI) reported Q2 EPS of ($0.05), $0.02 better than the analyst estimate of ($0.07). Revenue for the quarter came in at $7.16 million versus the consensus estimate of $6.02 million.
Revenue Growth Guidance in 2021 Revised to Exceed 80% Over 2020For earnings history and earnings-related data on CASI Pharma (CASI) click here.
... More